New drug on the horizon
It’s all very exciting at the moment as there seems to be a new line of drugs coming through trials that seem to have a significant impact on patients and their outcomes. Novartis said on Friday its drug Serelaxin, a treatment for acute heart failure, received breakthrough therapy status from the Food and Drug Administration in the US.
The drug is intended to treat symptoms of acute heart failure episodes. Novartis said there are about 3.5 million of those in the U.S. and European Union every year.
Novartis said patients treated with Serelaxin in a late-stage trial were 37% less likely to die in the six months after a heart failure episode compared with patients who received standard treatment.
The FDA created the breakthrough therapy program in 2012 as a way to speed up the approval process for drugs that could be significant improvements in the treatment of serious or life-threatening diseases from what’s currently on the market.